Treatment of diabetic retinopathy with long-acting somatostatin analogues
Medical Channel. 2001; 7 (4): 6-14
en Inglés
| IMEMR
| ID: emr-57601
ABSTRACT
In this chapter we will discuss the prevalence of diabetes mellitus and the natural course of diabetic retinopathy. Evidence for the important role of hyperglycaemia as the major risk factor for the development of this specific diabetic complication is described. Large clinical trials have provided information on how the risk for microvascular complications in diabetic patients could be modified Failures of existing preventive strategies and the need for the development of new treatment modalities are described. The important roles of growth hormone [GH] and other growth factors for the development of proliferative retinopathy and their modification by somatostatin as well as somatostatin analogues are discussed as a novel basis for the intervention strategies in proliferative diabetic retinopathy
Buscar en Google
Índice:
IMEMR (Mediterraneo Oriental)
Asunto principal:
Somatostatina
/
Octreótido
/
Factores de Riesgo
/
Sustancias de Crecimiento
/
Medicina Basada en la Evidencia
/
Diabetes Mellitus
/
Retinopatía Diabética
Límite:
Humanos
Idioma:
Inglés
Revista:
Med. Channel
Año:
2001
Similares
MEDLINE
...
LILACS
LIS